The Medicines Company (MDCO)
Россия
  • Россия
  • Украина

The Medicines Company (MDCO)

Contact Details

8 Sylvan Way, Parsippany, New Jersey, USA 07054-3801
(973) 656-1616
8 Sylvan Way, Parsippany, New Jersey, USA 07054-3801

General Information

Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.

Contact Information

Phone(973) 656-1616
Customer Service Phone(800) 947-5227
Fax(973) 656-9898
Website 1http://www.themedicinescompany.com
FacebookFacebook
LinkedInLinkedIn
Twitter@MDCONews
Thomson Reuters PermID4295900476

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and Chairman of the Board$5,193,285201413.5%
CFO and President$2,662,3632014-2.7%
CAO and Senior VP$1,219,73620148.0%
Former Executive VP and Former Other Executive Officer$2,674,5012014
Former Executive VP and Former Other Executive Officer$3,367,0722014

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsAugust 12, 2008$0
Department of Veterans AffairsDrugs and BiologicalsJune 13, 2003$0

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$309 million
Employees614

Ownership

Ticker SymbolMDCO
ExchangeNASDAQ Global Select Market
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Other CategorizationsManufacturer of Goods
Year Founded1996

Stocks

Previous Close33.47
Open33.79
Bid32.28 x 200
Ask32.30 x 2,900
Day`s Range31.95 - 34.31
52-Week Range25.58 - 43.31
Average Volume (1M)708,059
Beta0.63x
Market Cap.$2,330.01 Million
Last Dividend Amount0
1y Target Price Est.42

Corporate Venture Capital Investments

Companies Abbott Laboratories Has Invested In

CompanyCurrent StageIndustryEarliest InvestmentDate
Annovation Biopharma Inc.Exited (Acquired)BiotechnologySeries A ($8,000,000)09/11/12

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue19,34172,67890,472126,516
Cost of Revenue(37,775)86,97036,99933,737
Gross Profit57,116(14,292)53,47392,779
Research Development33,31630,12036,22123,949
Selling General and Administrative78,68682,47796,24680,534
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses74,227199,567169,466138,220
Other Income/Expenses Net----
Earnings Before Interest and Taxes(54,886)(126,889)(78,994)(11,704)
Interest Expense9,5909,5479,3488,607
Income Before Tax(64,021)(130,588)(67,837)10,783
Income Tax Expense11,225(25,447)(21,298)5,777
Minority Interest----
Net Income from Continuing Ops(75,246)(105,141)(46,539)5,006
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items(130,820)9(53)28
Net Income(206,066)(105,132)(46,592)5,034
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(206,066)(105,132)(46,592)5,034